Intravenous Compared to Oral Busulfan with Cyclophophamide for Allogeneic Hematopoietic Progenitor Cell Transplant Conditioning for AML and MDS

被引：0
|
作者：
Sobecks, Ronald
Rybicki, Lisa [1 ]
Kalaycio, Matt
Dean, Robert
Andresen, Steven [1 ]
Pohlman, Brad
Bolwell, Brian J.
Copelan, Edward A.
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1427 / 1428
页数：2
相关论文
共 50 条
  • [31] Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML
    El Chaer, Firas
    Borate, Uma
    Dulery, Remy
    Holtan, Shernan G.
    Law, Arjun Datt
    Muffly, Lori
    Nassereddine, Samah
    Shallis, Rory M.
    Stringaris, Kate
    Taylor, Justin
    Devine, Steven M.
    Mohty, Mohamad
    Hourigan, Christopher S.
    BLOOD ADVANCES, 2021, 5 (06) : 1757 - 1759
  • [32] Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: Myeloablation with reduced toxicity
    Shimoni, A
    Bielorai, B
    Toren, A
    Hardan, I
    Avigdor, A
    Yeshurun, M
    Ben-Bassat, I
    Nagler, A
    EXPERIMENTAL HEMATOLOGY, 2003, 31 (05) : 428 - 434
  • [33] Intravenous Busulfan-Based Conditioning Regimens in Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Lymphoblastic Leukemia
    Ko, Sun-Hye
    Lee, Jung-Hee
    Park, Han-Seung
    Lee, Je-Hwan
    Choi, Eun-ji
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Lee, Kyoo Hyung
    BLOOD, 2017, 130
  • [34] PHARMACOKINETIC (PK) COMPARISON OF INTRAVENOUS VERSUS ORAL BUSULFAN CONDITIONING REGIMENS FOR ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) PATIENTS
    Hutcherson, D. A.
    Surati, M.
    Sanvidge, K.
    Harvey, D.
    Al-Baldawi, R. N.
    Langston, A.
    Flowers, C.
    Lonial, S.
    Kaufman, J.
    Lechowicz, M. J.
    Waller, E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 154 - 155
  • [35] Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
    de Lima, M
    Couriel, D
    Thall, PF
    Wang, XM
    Madden, T
    Jones, R
    Shpall, EJ
    Shahjahan, M
    Pierre, B
    Giralt, S
    Korbling, M
    Russell, JA
    Champlin, RE
    Andersson, BS
    BLOOD, 2004, 104 (03) : 857 - 864
  • [36] Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS
    Rasor, Brendan
    Dickerson, Tyler
    Zhao, Qiuhong
    Elder, Patrick
    Brammer, Jonathan E.
    Larkin, Karilyn
    Jaglowski, Samantha
    Mims, Alice
    Penza, Sam
    Vasu, Sumithira
    Wall, Sarah A.
    William, Basem
    Saad, Ayman
    Roddy, Julianna V. F.
    Choe, Hannah
    Puto, Marcin
    LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 944 - 951
  • [37] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (SCT) USING FLUDARABINE/TREOSULFAN CONDITIONING REGIMEN COMPARED WITH BUSULFAN-BASED MYELOABLATIVE AND REDUCED-INTENSITY CONDITIONING IN PATIENTS WITH AML AND MDS; RELATIVE OUTCOMES DEPEND ON DISEASE STATUS AT SCT
    Shimoni, A.
    Shem-Tov, N.
    Rand, A.
    Volchek, Y.
    Yerushalmi, R.
    Hardan, I
    Nagler, A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S231 - S231
  • [38] Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine/Treosulfan Conditioning Regimen Compared with Busulfan-Based Myeloablative and Reduced-Intensity Conditioning in Patients with AML and Mds; Relative Outcomes Depend On Disease Status at Transplantation
    Shimoni, Avichai
    Rand, Avital
    Shem-Tov, Noga
    Hardan, Izhar
    Volchek, Yulia
    Maayaan, Hannah
    Yerushalmi, Ronit
    Nagler, Arnon
    BLOOD, 2009, 114 (22) : 1303 - 1304
  • [39] BUSULFAN/CYCLOPHOSPHAMIDE VS. BUSULFAN/FLUDARABINE CONDITIONING FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML/MDS: A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
    Song, I.
    Ryu, H.
    Choi, Y.
    Lee, H.
    Yun, H.
    Kim, S.
    Jo, D.
    HAEMATOLOGICA, 2013, 98 : 656 - 657
  • [40] Microbiota analysis in allogeneic stem cell transplant patients with in AML and MDS
    Gurer, Ekin Ece
    Oguz, Fatma Savran
    Aktas, Zerrin
    Kalayoglu, Sevgi Besisik
    Oncul, Mustafa Oral
    Sezerman, Osman Ugur
    Ekren, Berkay
    Caliskan, Kader
    Gulbas, Zafer
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 326 - 326
12345